Uncategorized Archives - Page 5 of 142

TuesdayJul 08, 2025 9:00 am

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary to Acquire 49% Stake in Prominent Florida Neuropsychiatry Clinic

The acquisition of Cohen and Associates, a respected interventional psychiatry practice, by NRx subsidiary HOPE Therapeutics, is expected to be immediately accretive to revenue and EBITDA. Cohen, serving the Sarasota-Bradenton area in Florida, specializes in treatments, including ketamine and TMS, for mood disorders, PTSD, and suicidal depression. HOPE Therapeutics is expanding toward a target of 30 clinics with a $100 million run rate by the end of 2025. NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, and its wholly-owned subsidiary HOPE Therapeutics, Inc., a multi-site clinical care delivery organization, recently signed a binding letter of intent to acquire a 49%…

MondayJul 07, 2025 11:50 am

Clene Inc. (NASDAQ: CLNN) to Conduct Neurofilament Biomarker Analysis for CNM-Au8(R) in ALS in Early Q4 2025

The FDA offered supportive feedback on Clene’s proposed statistical analysis plan during a recent Type C meeting. The neurofilament biomarker analysis results could support an accelerated approval submission for CNM-Au8 later in 2025. Clene has two additional FDA meetings scheduled in Q3 2025 to discuss ALS survival data and its MS program. Nearly 200 ALS patients are participating in the NIH-sponsored Expanded Access Program for CNM-Au8. The analysis aims to validate the neuroprotective effects shown in previous HEALEY Platform Trial results. Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial…

ThursdayJul 03, 2025 11:15 am

Nutriband Inc. (NASDAQ: NTRB) Added to Four Key Indexes, Rethinking Opioid Safety in a Time of Crisis

Nutriband and Kindeva have completed commercial-scale manufacturing for AVERSA(TM) Fentanyl, a major milestone in the path to FDA approval Updated analyst report raises NTRB’s price target to $15.00 and reiterates an Outperform rating, citing favorable trial pathway and strong execution Aversa abuse-deterrent tech is protected by international patents and may address a global unmet need in safe pain management NTRB boosting their profile and credibility with its recent membership to the Russel Indexes The opioid crisis remains one of the most pressing public health challenges of our time. While synthetic opioids like fentanyl play a crucial role in managing severe…

WednesdayJul 02, 2025 9:45 am

Adageis: An AI-Powered Advocate for Healthcare Providers

Adageis, a company offering a powerful and patented AI-centric software solution, remains committed to streamlining the healthcare sector, making it easier for providers to meet their financial goals It works with over 90 Electronic Health Record platforms, an unrivalled level of access that gives its users actionable insights at the point of care The company covers over 260,000 patient lives, and looks to double that to 580,000, achieving its $100,000 monthly recurring revenue target Adageis, a company offering powerful and patented AI-based software, provides flexible healthcare and related software solutions for providers and healthcare systems. The company remains committed to…

WednesdayJul 02, 2025 9:00 am

Soligenix Inc. (NASDAQ: SNGX) Highlights Encouraging Phase 3 Progress for HyBryte(TM) in Investment Webinar

A focus during the webinar was the investigator-initiated study currently being conducted at the University of Pennsylvania under the leadership of Dr. Ellen Kim. Interim results show that among the first eight patients who completed 18 weeks of treatment, 75% demonstrated a greater than 50% reduction in disease severity. Soligenix anticipates top-line results from the phase 3 trial in the second half of 2026. In a recent webinar hosted by Allele Capital, Soligenix (NASDAQ: SNGX) executives Dr. Christopher Schaber and Dr. Christopher Pullion shared detailed updates on the company’s HyBryte(TM) (synthetic hypericin) clinical development (https://ibn.fm/dz7eO). The event offered an in-depth look at…

FridayJun 27, 2025 9:45 am

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Applies for FDA Commissioner’s National Priority Voucher for IV Ketamine NRX-100

The new FDA voucher program aims to speed approval of drugs aligned with national health priorities. NRX-100, a preservative-free ketamine, is also under an Abbreviated New Drug Application (“ANDA”) with a priority review request. NRx has submitted full CMC data and draft labeling for NRX-100, meeting key Commissioner’s National Priority Voucher pre-qualification criteria. The company’s U.S.-based manufacturing aims to reduce foreign supply chain dependence and address diversion concerns. A patent on the preservative-free process and a citizen petition to withdraw preserved ketamine could bolster NRx’s market position. NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company developing innovative treatments for suicidal depression and…

ThursdayJun 26, 2025 9:45 am

Lantern Pharma Inc.’s (NASDAQ: LTRN) AI-Powered Platform Delivers Promising and Durable Results in Lung Cancer Trial

Lantern Pharma uses a proprietary AI platform, RADR®, to guide its oncology drug development, enabling rapid drug candidate identification and targeted trial design based on genomic and biomarker data. A Phase 2 trial patient achieved a complete response in their primary cancer lesions after multiple prior therapies failed and has remained responsive to LP-300 for two years signaling durable clinical benefit in this challenging population. The target population, never-smokers with non-small cell lung cancer, represents a growing global unmet need estimated at over $4 billion annually. Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company leveraging artificial intelligence and machine learning…

FridayJun 20, 2025 9:45 am

Nutriband Inc. (NASDAQ: NTRB) Reimagining Drug Safety Through Scalable Innovation

Nutriband Inc. has been granted a new U.S. patent for its AVERSA(TM) transdermal abuse-deterrent technology, expanding its domestic IP coverage AVERSA(TM) is designed to prevent misuse, abuse, and accidental exposure of transdermal drugs with abuse potential, such as fentanyl With overdose deaths still plaguing the U.S., Nutriband’s platform has the potential to enhance drug safety across multiple therapeutic categories The opioid crisis remains one of the most persistent public health emergencies in the U.S. While state and federal initiatives have helped curb some of the worst-case trajectories, more than 100,000 Americans still die each year from drug overdoses, a significant proportion linked to synthetic…

WednesdayJun 18, 2025 10:30 am

Soligenix Inc. (NASDAQ: SNGX) Proprietary Therapy Shows Promise in Treatment of Psoriasis

Psoriasis affects approximately 3% of the adult population in the United States, translating to more than 7.5 million individuals. By using visible light, Soligenix’s SGX302 aims to mitigate risks while effectively reducing inflammation and promoting skin healing. A phase 2a study demonstrated that SGX302 was well tolerated, with no significant adverse events reported. Psoriasis is more than just a skin condition — it’s a lifelong autoimmune disorder that disrupts daily life with painful, inflamed patches and an emotional toll that can be just as severe as the physical symptoms. Soligenix (NASDAQ: SNGX) is at the forefront of developing innovative therapies…

TuesdayJun 17, 2025 9:45 am

Soligenix Inc. (NASDAQ: SNGX) Makes Advancement in Proprietary Treatment for Behçet’s Disease

Behçet’s disease is more prevalent in countries along the Silk Road, including Türkiye, Iran and Japan. Even with treatment, symptoms can continue occurring for many patients and significantly affect their quality of life and productivity. Soligenix has initiated a clinical trial to evaluate the safety, tolerability and preliminary efficacy of SGX945 in patients suffering from oral ulcers. Behçet’s disease is a rare, chronic autoimmune disorder characterized by inflammation of blood vessels, leading to a range of symptoms including painful mouth and genital ulcers, eye inflammation and skin lesions. With limited treatment options available, Soligenix (NASDAQ: SNGX) is at the forefront of…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary to Acquire 49% Stake in Prominent Florida Neuropsychiatry Clinic

Clene Inc. (NASDAQ: CLNN) to Conduct Neurofilament Biomarker Analysis for CNM-Au8(R) in ALS in Early Q4 2025

Nutriband Inc. (NASDAQ: NTRB) Added to Four Key Indexes, Rethinking Opioid Safety in a Time of Crisis

Adageis: An AI-Powered Advocate for Healthcare Providers

Soligenix Inc. (NASDAQ: SNGX) Highlights Encouraging Phase 3 Progress for HyBryte(TM) in Investment Webinar

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Applies for FDA Commissioner’s National Priority Voucher for IV Ketamine NRX-100

Lantern Pharma Inc.’s (NASDAQ: LTRN) AI-Powered Platform Delivers Promising and Durable Results in Lung Cancer Trial

Nutriband Inc. (NASDAQ: NTRB) Reimagining Drug Safety Through Scalable Innovation

Soligenix Inc. (NASDAQ: SNGX) Proprietary Therapy Shows Promise in Treatment of Psoriasis

Soligenix Inc. (NASDAQ: SNGX) Makes Advancement in Proprietary Treatment for Behçet’s Disease

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search